DexCom, Inc. — Blitz Index 52 (C)
Dexcom scores 52 — a measured recovery after the 2024 collapse, with margins expanding again, but Stelo's consumer bet is still unprovable in the filings.
Confidence: High · Category: platforms
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 15 / 25 | Revenue $3,622M → $4,033M → $4,662M re-accelerated; customer adds 500–600K → 600–700K — but Stelo contributes zero provable revenue (undisclosed) |
| B · Moat | 32 / 60 | Payer formulary position + AID pump integrations + Clarity workflow lock-in — a moat, but the AID corridor is shared with Abbott (B1 capped at 7) |
| C · Creative destruction | 11 / 15 | Displacing fingersticks and expanding into Type 2 non-insulin — the clinical-regulatory case (CONNECT RCT, Smart Basal FDA) is building |
| D · BlitzFailing | −6 | FDA warning letter (2025-03) and ongoing G6/G7 class actions (−3) plus securities litigation around the 2024 guidance cut (−2) |
Radar axes (0–100): Moat 53.3 · Speed 60 · Creative 73.3.
Watch item
Gates: G1 ✓ (re-acceleration documented) · G2 ✓ (borderline — bar $46.62B (FY25 revenue × 10) vs derived ceiling ~$62–68B from 52M covered lives; thin at 1.3–1.5x, and the company's own trajectory lags far behind).
Strengths
- Consumables repeat revenue (~95%) + customer adds re-accelerating (500–600K → 600–700K) — PMF proven in physical metrics
- International revenue +16.1% (FY25) · +19–26% (2026 quarters) — the next growth engine is measured
- FCF $1,077.2M (margin 23.1%) + buybacks ($750M FY24 · $500M FY25 · $603.6M 1H26) — self-funding phase
- GM 60.1% → 63.4% + operating margin 19.6% → 22.9% (1H26) — recovery in growth and margin together
- Abbott patent dispute settled (2024 settlement · cross-license, no-sue through 2034-12-20) — legal risk on competition removed
- CONNECT RCT (Q2 2026) + Smart Basal FDA clearance (2025-12) — clinical and regulatory footing accumulating for Type 2 non-insulin adoption
Concerns
- FDA warning letter (2025-03, manufacturing · quality systems) + G6/G7 class actions — regulatory and legal risks are realized facts
- Securities class action over the 2024 guidance cut is proceeding — a credibility discount on forward statements
- Stelo revenue is undisclosed — the second curve (OTC · consumer) cannot be verified in current filings
- ASP pressure from rebate eligibility expansion and channel mix (10-K MD&A) — penetration growth may not convert to revenue
- New-patient share race with Abbott is tight (PCP survey 47/46 · endocrinology 53/44) — no hard-number share lead
- The 2024 sales-org overhaul shock may recur + CEO change (Leach, 2026) — execution continuity
Next earnings
Oct 29, 2026 · After close · Confirmed
Coverage
DexCom, Inc. · Q3 2026 earnings Oct 29, 2026 (AMC, confirmed) · Score 52 · Grade C
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.